Browsing by Author "Husain, Nuzhat"
Now showing 1 - 15 of 15
Results Per Page
Sort Options
Item Bilateral primary B-cell lymphoma of testis in a three-year-old male child.(2010-01) Kumari, Malti; Husain, Nuzhat; Babu, Suresh; Kureel, S NItem Do phosphatase of regenerating liver‑3, matrix metalloproteinases‑2, matrix metalloproteinases‑9, and epidermal growth factor receptor‑1 predict response to therapy and survival in glioblastoma multiforme.(2016-07) Soni, Priyanka; Husain, Nuzhat; Chandra, Anil; Ojha, Bal Krishan; Bhatt, Madan Lal Brahma; Gupta, Rakesh KumarContext: Poor survival of the glioblastoma multiforme (GBM) has been attributed in part to the invasive nature of the lesion making complete surgical removal near impossible. Phosphatase of regenerating liver‑3 (PRL‑3), matrix metalloproteinases‑2 and ‑9 (MMP‑2 and MMP‑9), and epidermal growth factor receptor (EGFR‑1) play a role in invasive nature of tumor cells. Aims: This study was conducted to evaluate PRL‑3, MMP‑2, MMP‑9, and EGFR‑1 (markers) expression in cases to GBM and to correlate their expression with therapy response and survival. Settings and Design: GBM cases (n = 62) underwent surgery followed by radiation (n = 34) and chemoradiation (n = 28). Using WHO Response Evaluation Criteria in Solid Tumors criteria response to therapy was assessed at 3 months and cases followed up for survival. Subjects and Methods: Expression of markers was assessed by immunohistochemistry as a percentage of positive tumor cells in hot spots. Statistical Analysis Used: Kaplan–Meier, ANOVA, Chi‑square test, univariate, and multivariate Cox‑regression analysis was done. Results: Response to therapy was evident in 54.8% cases of responders with the mean survival of 494.03 ± 201.13 days and 45.2% cases of non responders (278.32 ± 121.66 days) with P = 0.001. Mean survival for the patient’s opted chemoradiation was 457.43 ± 222.48 days which was approximately 3 months greater than those who opted radiation alone (P = 0.029). We found PRL‑3 overexpression was an independent, significant, poor prognostic factor for survival by multivariate analysis (P = 0.044). Cases negative for MMP’s and EGFR showed increased survival, but the difference was insignificant. Conclusion: PRL‑3 expression appears to be related to an adverse disease outcome.Item Increased expression of ADAM33 protein in asthmatic patients as compared to non-asthmatic controls.(2013-03) Tripathi, Priya; Awasthi, Shally; Husain, Nuzhat; Prasad, Rajendra; Mishra, VikasBackground & objectives: ADAM33 is a member of a family of genes that encode membrane-anchored proteins with a disintegrin and a metalloprotease domain, primarily expressed in lung fibroblasts and bronchial smooth muscle cells. ADAM33 has been identified as a risk factor for asthma and is known as a gene associated with airway remodelling. The present study was conducted with the aims to investigate the expression of ADAM33 protein in patients of asthma and non-asthmatic controls, and to assess if the expression of ADAM33 protein relates with severity of asthma. Methods: A total of 35 subjects, including 27 patients with asthma and eight non-asthmatic controls were included using Global Initiative for Asthma guidelines 2005. Bronchial biopsy tissues were collected and paraffin sections were made to store all study samples. Immunohistochemistry was performed using standardized protocol. Results: An increase in expression of ADAM33 protein was observed in the epithelium, smooth muscle and mesenchymal cells of asthma cases when compared to controls but there was no relationship with severity of asthma. Interpretation & conclusions: A higher expression of ADAM 33 protein was seen in asthma patients compared to controls. Large prospective studies need to be done with adequate study design to confirm these preliminary finding.Item Multiple inflamed cutaneous nodules in an elderly female(Indian Association of Dermatologists, Venereologists & Leprologists, 2018-07) Malhotra, Kiran Preet; Neyaz, Azfar; Gupta, Arsh; Das, Monjyoti; Husain, NuzhatItem Multiple inflamed cutaneous nodules in an elderly female(Indian Association of Dermatologists, Venereologists & Leprologists, 2018-07) Malhotra, Kiran Preet; Neyaz, Azfar; Gupta, Arsh; Das, Monjyoti; Husain, NuzhatItem Papillary variant of medullary carcinoma thyroid.(2014-01) Shukla, Saumya; Awasthi, Namrata P; Husain, NuzhatItem Prognostic Value of CA19-9 and CA242 in Gallbladder Cancer - An Exploratory Study(International Society for Contemporary Medical Research, 2019-06) Agarwal, Akash; Tiwari, Vandana; Kumari, Swati; Husain, NuzhatIntroduction: There are, at present, no biomarkers topredict to prognosis of Gallbladder cancer. We conducted aprospective exploratory study to evaluate the role to serum CA19-9 and CA 242 as prognostic markers.Material and Methods: We enrolled consecutive patients forthis study and CA 19-9 and 242 were estimated from venoussamples. Association of these markers with clinical variablesand median overall survival (OS) difference between patientswho has raised versus normal levels of these markers wasdetermined.Results: Sixty-two patients were enrolled for this study.Forty-four (71%) patients had elevated CA19-9. Thirty-nine(62.9%) patients had an raised CA242 levels. CA 19-9 wasfound to be significantly associated with the presence ofjaundice (p=0.038) and advanced stage (p=0.009). MedianOS of patients who had elevated CA 19-9 was 5.73 monthscompared to 8.33 months in patients who had normal CA19-9. The difference was not statistically different (p= 0.15).Median OS for patients who had elevated CA 242 was 5.53months, which was inferior to those who had normal levels(9.1 months). This difference approached, but was notstatistically significant (p=0.055).Conclusion: This is the first study to show associationbetween CA 19-9 and stage of disease in GBC. At present,CA 19-9 and CA 242 cannot be recommended as prognosticmarkers. However, role of CA 242 needs to be examined ina larger cohort of patients of GBC to establish its usefulness.Item Proliferating cell nuclear antigen, p53 and micro vessel density: Grade II vs. Grade III astrocytoma.(2010-01) Malhan, Priya; Husain, Nuzhat; Bhalla, Shalini; Gupta, Rakesh K; Husain, MazharHistological classification and grading are prime procedures in the management of patients with astrocytoma, providing vital data for therapeutic decision making and prognostication. However, it has limitations in assessing biological tumor behavior. This can be overcome by using newer immunohistochemical techniques. This study was carried out to compare proliferative indices using proliferating cell nuclear antigen (PCNA), extent of p53 expression and micro vessel morphometric parameters in patients with low grade and anaplastic astrocytoma. Twenty-five patients, each of grade II and grade III astrocytoma were evaluated using monoclonal antibodies to PCNA, p53 protein and factor VIII related antigen. PCNA, p53-labeling indices were calculated along with micro vessel morphometric analysis using Biovis Image plus Software. Patients with grade III astrocytoma had higher PCNA and p53 labeling indices as compared with grade II astrocytoma (29.14 plus/minus 9.87% vs. 16.84 plus/minus 6.57%, p 0.001; 18.18 plus/minus 6.14% vs. 6.14 plus/minus 7.23%, p 0.001, respectively). Micro vessel percentage area of patients with grade III astrocytoma was also (4.26 plus/minus 3.70 vs. 1.05 plus/minus 0.56, p 0.001), higher along with other micro vessel morphometric parameters. Discordance between histology and one or more IHC parameters was seen in 5/25 (20%) of patients with grade III astrocytoma and 9/25 (36%) of patients with grade II disease. PCNA and p53 labeling indices were positively correlated with Pearson's correlation, p less than 0.001 for both). Increased proliferative fraction, genetic alterations and neovascularization mark biological aggressiveness in astrocytoma. Immunohistochemical evaluation scores over meet the challenge of accurate prognostication of this potentially fatal malignancy.Item Proliferating trichilemmal cyst with nodal enlargement mimicking metastatic squamous cell carcinoma.(2015-07) Malhotra, Kiran Preet; Shukla, Saumya; Singhal, Ashish; Husain, NuzhatItem Retroperitoneal ectomesenchymoma: A rare childhood tumor.(2010-01) Misra, Sheenu; Husain, NuzhatItem Revisiting epidermal growth factor receptor in glioblastoma multiforme: Does it play a role in response to therapy.(2014-07) Soni, Priyanka; Husain, Nuzhat; Awasthi, Rishi; Chandra, Anil; Ojha, Bal K; Gupta, Rakesh KBackground and Aim: Glioblastoma multiforme (GBM) are the most aggressive class of cancer of central nervous system with hallmark characteristics that include rampant proliferation, necrosis, and endothelial proliferation. Epidermal growth factor receptor (EGFR) has been implicated as the primary contributor to glioblastoma initiation and succession. The present study was designed to evaluate EGFR protein expression in GBM as predictor of response to therapy and survival. Materials and Methods: Epidermal growth factor receptor was assessed by immunohistochemistry as a percentage of positive tumor cells in hot spots (10 high-power fields). The study group comprised of 35 cases of GBM. All cases underwent surgical resection and subsequently underwent radiotherapy (n = 17) or radiotherapy with adjuvant temozolomide chemotherapy (n = 18). Immediate response to therapy was assessed at 3 months using World Health Organization response evaluation criteria in solid tumors criteria and cases followed up for survival. Results: Twenty-four cases (68.6%) expressed EGFR while 11/35 (31.4%) cases were negative. Response to therapy was evident in 21/35 cases (60.0%) and 14/35 were (40.0%) nonresponders. Mean EGFR protein expression in responders was 37.23 ± 33.70 and in nonresponders was 59.5 ± 39.46 (P = 0.542). The percentage of responders which were EGFR negative was 72.7% and while response in EGFR positive cases was observed in 54.2%. Mean survival in EGFR positive and negative GBM was 394.37 ± 189.11 and 420.54 ± 191.23 days, respectively. Conclusion: The EGFR negative cases appear to respond better to therapy, however, the difference is not statistically significant (P = 0.298). Further, EGFR protein expression does not play a definitive role in predicting survival. This is an original study evaluating EGFR in terms of therapeutic response.Item A Study of the Clinical, Pathological and Radiological Profile of Lung Cancer in Non-Smokers(Ibn Sina Academy of Medieval Medicine & Sciences, 2019-09) Silpa, Kshetrimayum; Vaskarjeet, Konsam; Srivastava, Anand; Kant, Surya; Husain, NuzhatAim and Objective: To study the clinical, pathological andradiological profile of lung cancer in non-smokers in a tertiarycare center.Methods: 53 non-smokers diagnosed with lung cancerattending the Department of Respiratory Medicine, KingGeorge’s Medical College from September 2015 to August2017 were enrolled. Record of all diagnostic investigations andprocedures performed namely transthoracic fine needleaspiration cytology (FNAC) and biopsy, bronchoscopy,thoracoscopy, closed pleural biopsy, lymph-node FNAC andbiopsy, routine blood and sputum examinations and a detailedhistory were obtained. Data was analysed retrospectively.Results: The mean age of presentation was 53.8±11.6 years.Majority were females (60.4%). Most common presentingsymptom was cough (84.9%). Mean duration of symptoms was6.9 months. Pallor was the most common clinical examinationfinding (41.5%). Mass with effusion was the most commonradiological lesion (45.3%). 22.6% masses were centrallylocated. Transthoracic biopsy could diagnose 32 (60.4%)cases. Adenocarcinoma was the most common type in bothmales (76.2%) and females (78.1%). Epidermal growth factorreceptor (EGFR) mutation was positive in 46.3% ofadenocarcinoma. Exon 19 deletion was the more commonmutation.Conclusion: Lung cancer among never smokers is a distinctclass with risk factors and genetic features discrete from thoseassociated with tobacco smoke. Indoor air pollutants as well asETS are definitely implicated risk factors. Targetable mutationsare commoner in non-smokers and hence mutation testingshould always be done in such patients. It is important toconduct studies about the diverse characteristics of this entityto consolidate our knowledge of this growing group of cancer.Item A study to evaluate asbestos fiber burden in lung and pleural malignancies.(2010-07) Verma, S K; Srivastava, Rahul; Kant, Surya; Prasad, R; Garg, R; Ahmad, Iqbal; Husain, NuzhatBackground: There is scarcity of data on asbestos fiber burden in lung and pleural malignancies. Aim: To evaluate asbestos fiber burden in biopsy samples of suspected lung and pleural malignancies. Study Design: This was a single-centre, observational study. Study Period: From August 2010 to July 2010. Setting: Department of Pulmonary Medicine, CSMMU, UP, Lucknow, a tertiary care hospital in India. Study Population: Suspected cases of lung and pleural malignancy. Materials and Methods: Biopsy tissues taken by computed tomography (CT)-guided biopsy, bronchoscopic biopsy, and pleural biopsy by Cope's needle were analyzed for histopathology and asbestos burden by Haq et al.'s method. Results: 20 patients were studied. Mean fiber burden was 9.25 × 10 4 fibers/g. Average burden in lung malignancies (11 patients) was 9.178 × 10 4 fibers/g and in pleural tissue (9 patients) was 9.332 × 10 4fibers/g. Among the different cell types, mean fiber burden in squamous cell carcinoma was 8.99 × 10 4 fibers/g, in adenocarcinoma was 9.71 × 10 4 fibers/g, and in small cell carcinoma was 7.54 × 10 4 fibers/g. Mean fiber burden in bronchoscopic endobronchial biopsy tissue was 10.69 × 10 4 fibers/g, while in CT-guided biopsy was 8.60× 10 4fibers/g. Conclusion: Maximum number of fibers was found in adenocarcinoma.Item Utility of cysticercus fasciolaris antigen in Dot ELISA for the diagnosis of neurocysticercosis.(2008-06-08) Shukla, Nitin; Husain, Nuzhat; Agarwal, Girdhar G; Husain, MazharBackground: Clinical diagnosis of neurocysticercosis (NC) is established by CT scan and MRI. However, absolute diagnosis is not possible in a fair number of cases, and serological assays are used as adjunct. Besides, CT scan and MR imaging are resource-intensive tests and not practical for screening in endemic areas. Aim: To provide a low-cost, efficient, and reproducible assay for the detection of antibodies against cysticerci. Hence we have attempted to standardize and evaluate the diagnostic utility of the cysticercus fasciolaris antigen in a Dot ELISA assay for diagnosis of NC. Setting and Design: Tertiary hospital-based, case-control series. Materials and Methods: Confirmed cases of NC diagnosed by presence of ring lesions in CT scan or MR imaging with presence of scolex were taken as positive controls (n = 50). Negative controls (n = 50) included subjects with normal CT scan studies (n = 30) and diseased controls with ring lesions in CT scan confirmed to be neurotuberculosis (n = 20). Dot ELISA was standardized and validated with commercially available ELISA (UBI, USA) using sera from the study groups. Statistical Analysis: Chi-square test was used to compare the immunodiagnostic performance of the two tests. P value less than .05 (P < 0.05) was considered significant. Results: The Dot ELISA had a sensitivity of 88% and specificity of 74% with a positive predictive value of 77.19% and negative predictive value of 81.06%. Likelihood ratios for a positive and a negative test were 3.4 and 0.2. The sensitivity and specificity of commercial ELISA were 92% and 84% respectively. Difference between the performances of the two tests was not significant statistically. Conclusions: Dot ELISA has sensitivity and specificity comparable to ELISA for the diagnosis of NC. The test is simpler, not requiring expertise and instrumentation. Further validation of the test as a screening tool is required.Item Vesicular pleuritis in a case of tuberculous empyema thoracis.(2010-10) Husain, Nuzhat; Kumari, Malti; Tandon, Shekhar